Skip to main content

RenovoRx, Inc.

corporate_fare Company Profile

RenovoRx, Inc.

RNXT·NASDAQ·Industrial Applications And Services·CIK 0001574094

RenovoRx is a life sciences company that develops targeted oncology therapies and commercializes RenovoCath, a local drug-delivery device. The company's mission is to improve the lives of cancer patients by providing innovative solutions for targeted delivery of therapeutic agents. RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which uses RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site (intra-arterial, or IA delivery). This approach aims to bathe the target tumor while potentially minimizing toxicities compared to systemic intravenous therapy, offering increased safety, tolerance, and improved efficacy. RenovoCath is cleared by the U.S. Food and Drug Administration (FDA) for temporary vessel occlusion in applications such as arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx is actively commercializing the TAMP therapy platform and RenovoCath as a stand-alone device within its FDA-cleared fields of use in the United States. The company received its first commercial purchase orders for RenovoCath devices in December 2024. For the year ended December 31, 2025, RenovoRx generated an aggregate of $1.1 million in revenue from RenovoCath sales. These sales came from U.S. cancer centers that placed repeat orders and new institutions, including several high-volume National Cancer Institute-designated centers. In February 2026, 12 U.S. cancer centers were utilizing RenovoCath, and 21 additional centers were evaluating the device, had completed evaluation, or were preparing for activation. As of the date of this Report, a total of 33 centers have requested access to RenovoCath.

RenovoRx, Inc. (NASDAQ:RNXT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 30 items for RNXT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • RenovoRx Reports $1.1M RenovoCath Revenue in First Full Year, Confirms Strong Cash Position & Trial Progress
  • RenovoRx Appoints Dr. Ramtin Agah as Executive Chairman with $450K Base Salary and Bonus Eligibility
  • RenovoRx's TIGeR-PaC Phase III Trial Surpasses 100 Patients, Nears Enrollment Completion
  • RenovoRx CEO Invests $27,702 in Company's Recently Closed Private Placement
  • CFO Mark Voll Invests $110,808 in RenovoRx Through Private Placement, Acquiring Stock and Warrants

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.12M
Net Income
-$11.17M
Diluted EPS
-$0.32
Op. Cash Flow
-$10.97M
Free Cash Flow
-$10.97M
Gross Profit
$796K
Operating Income
-$12.51M
Cash & Equivalents
$7.02M
Debt / Equity
0.00×
Net Margin
-9.94×
Shares Outstanding
36.61M sh
Source: 10-K · filed 2026-05-15 · accession 0001193125-26-227256
$0.9518 +1.04% today
52-week range · as of 2026-11-05 $0.7006 – $2.59
Market cap
$45.45M
Volume
477.4K (1.0× avg)
3-mo avg 466.8K
Live data · 2026-11-22 12:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RNXT - Filings & News (Page 2)

RNXT
Mar 30, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $0.9518 info
Change: -$0.1182 (-11%) info
Market Cap: $45.452M info
RNXT
Mar 27, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $0.9518 info
Change: -$0.1682 (-15%) info
Market Cap: $45.452M info
RNXT
Mar 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $0.9518 info
Change: -$0.1679 (-15%) info
Market Cap: $45.452M info
RNXT
Mar 24, 2026, 9:16 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $0.9518 info
Change: -$0.1882 (-17%) info
Market Cap: $45.452M info
RNXT
Mar 24, 2026, 9:15 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $1.14
Real-time Price: $0.9518 info
Change: -$0.1882 (-17%) info
Market Cap: $45.452M info
RNXT
Mar 23, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.975
Real-time Price: $0.9518 info
Change: -$0.0232 (-2%) info
Market Cap: $45.452M info
RNXT
Mar 18, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.990
Real-time Price: $0.9518 info
Change: -$0.0382 (-4%) info
Market Cap: $45.452M info
RNXT
Feb 27, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.938
Real-time Price: $0.9518 info
Change: +$0.0138 (+1%) info
Market Cap: $45.452M info
RNXT
Feb 06, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9509
Real-time Price: $0.9518 info
Change: +$0.0009 (+0.09%) info
Market Cap: $45.452M info
RNXT
Jan 02, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8352
Real-time Price: $0.9518 info
Change: +$0.1166 (+14%) info
Market Cap: $45.452M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets